Literature DB >> 7507681

In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease.

A E Koch1, L B Kronfeld-Harrington, Z Szekanecz, M M Cho, G K Haines, L A Harlow, R M Strieter, S L Kunkel, M C Massa, W G Barr.   

Abstract

Cytokines and cellular adhesion molecules (CAMs) may play a role in the inflammatory and fibrotic processes underlying systemic sclerosis (SSc). We compared the immunohistological distribution of cytokines and CAMs in skin biopsies from 12 SSc patients and 14 normal (NL) individuals. Among CAMs, vascular cell adhesion molecule-1 (VCAM-1), which mediates leukocyte-endothelial adhesion, showed increased expression on SSc versus NL endothelium and stratum granulosum. P-selectin was up-regulated in SSc versus NL stratum granulosum. The CD44 lymphocyte homing receptor showed the most striking differences between SSc and NL: its expression was increased in SSc stratum granulosum, stratum spinosum, on lymphocytes, and macrophages. Regarding cytokines, interleukin-6 (IL-6) expression was increased on SSc versus NL endothelium and fibroblasts. Tumor necrosis factor-alpha (TNF-alpha) reactivity was more prevalent in SSc than NL stratum granulosum, whereas IL-8 expression was higher on SSc compared to NL endothelium. Some CAMs, such as VCAM-1 and P-selectin, and cytokines, namely TNF-alpha and IL-8, were more commonly found in skin biopsies taken from early (< or = 1 year's duration) SSc, while others, such as IL-6, showed up-regulation in the late stage of the disease. The results suggest that certain CAMs and cytokines may play a differential role in both the early, inflammatory, and the late, fibrotic stage of SSc.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7507681     DOI: 10.1159/000163802

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  45 in total

1.  Perivascular Adventitial Fibroblast Specialization Accompanies T Cell Retention in the Inflamed Human Dermis.

Authors:  Alexander M S Barron; Julio C Mantero; Jonathan D Ho; Banafsheh Nazari; Katharine L Horback; Jag Bhawan; Robert Lafyatis; Christina Lam; Jeffrey L Browning
Journal:  J Immunol       Date:  2018-12-03       Impact factor: 5.422

Review 2.  Functional autoantibodies in systemic sclerosis.

Authors:  Jeannine Günther; Judith Rademacher; Jakob M van Laar; Elise Siegert; Gabriela Riemekasten
Journal:  Semin Immunopathol       Date:  2015-08-21       Impact factor: 9.623

Review 3.  Fibrosis--a lethal component of systemic sclerosis.

Authors:  Yuen Yee Ho; David Lagares; Andrew M Tager; Mohit Kapoor
Journal:  Nat Rev Rheumatol       Date:  2014-04-22       Impact factor: 20.543

Review 4.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

5.  The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma.

Authors:  H Haghnegahdar; J Du; D Wang; R M Strieter; M D Burdick; L B Nanney; N Cardwell; J Luan; R Shattuck-Brandt; A Richmond
Journal:  J Leukoc Biol       Date:  2000-01       Impact factor: 4.962

6.  In situ evidence of pulmonary endothelial activation in patients with granulomatosis with polyangiitis and systemic sclerosis.

Authors:  Leticia Kawano-Dourado; Alexandre M Ab'Saber; Vera Luiza Capelozzi; Carla Valeri; Carmen Sílvia Valente Barbas
Journal:  Lung       Date:  2015-03-19       Impact factor: 2.584

7.  Musculoskeletal Involvement in SSc Is Associated with Worse Scores on Short Form-36 and Scleroderma Health Assessment Questionnaire and Lower Tumor Necrosis Factor-α Gene Expression in Peripheral Blood Mononuclear Cells.

Authors:  Eliza R Pelrine; Marie-Dominique Ah-Kioon; Meng Zhang; Franck J Barrat; Robert F Spiera; Jessica K Gordon
Journal:  HSS J       Date:  2016-07-22

8.  B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial.

Authors:  Silvia Bosello; Maria De Santis; Gina Lama; Cristina Spanò; Cristiana Angelucci; Barbara Tolusso; Gigliola Sica; Gianfranco Ferraccioli
Journal:  Arthritis Res Ther       Date:  2010-03-25       Impact factor: 5.156

9.  Global chemokine expression in systemic sclerosis (SSc): CCL19 expression correlates with vascular inflammation in SSc skin.

Authors:  Allison L Mathes; Romy B Christmann; Giuseppina Stifano; Alsya J Affandi; Timothy R D J Radstake; G Alessandra Farina; Cristina Padilla; Sarah McLaughlin; Robert Lafyatis
Journal:  Ann Rheum Dis       Date:  2013-07-19       Impact factor: 19.103

10.  Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin.

Authors:  Masahide Kubo; Joanna Czuwara-Ladykowska; Omar Moussa; Margaret Markiewicz; Edwin Smith; Richard M Silver; Stefania Jablonska; Maria Blaszczyk; Dennis K Watson; Maria Trojanowska
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.